Janus Kinase Inhibitors in the Treatment of Atopic Dermatitis: Military Considerations

被引：0
|
作者：
Nolan, Colin F. [1 ,2 ]
机构：
[1] Naval Med Readiness & Training Command San Diego, Dept Dermatol, San Diego, CA USA
[2] 34800 Bob Wilson Dr, San Diego, CA 92134 USA
来源：
CUTIS | 2022年 / 110卷 / 06期
关键词：
DOUBLE-BLIND; PLACEBO; ADOLESCENTS; ADULTS; UPADACITINIB; ABROCITINIB; EFFICACY; SAFETY;
D O I：
10.12788/cutis.0668
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Janus kinase (JAK) inhibitors represent one of the newest and most promising additions to the available treatments of atopic dermatitis (AD). Janus kinase inhibitors offer several key benefits over injectable biologics to include more predictable pharmacokinetics, nonimmunogenicity, and flexible dosing, in addition to their oral and topical bioavailability. Recommended laboratory assessments before and during treatment in addition to medication side effects may limit the scope of use in the active-duty military population and specifically within special-duty populations. In this article, we review approved and emerging JAK inhibitors for the treatment of AD as well as important considerations for both military and nonmilitary patient populations. © 2022 Quadrant Healthcom Inc.. All rights reserved.
引用
收藏
页码：316 / 320
页数：5
相关论文
共 50 条
  • [11] Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis
    Navarrete-Rodriguez, Elsy M.
    Larenas-Linnemann, Desiree
    de la Cruz, Helena Vidaurri
    Luna-Pech, Jorge A.
    Sangines, Esther Guevara
    CURRENT ALLERGY AND ASTHMA REPORTS, 2024, 24 (09) : 485 - 496
  • [12] The suitability of treating atopic dermatitis with Janus kinase inhibitors
    Narla, Shanthi
    Silverberg, Jonathan, I
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (05) : 439 - 459
  • [13] Use of Janus kinase inhibitors in atopic dermatitis - an update
    Dhar, Sandipan
    Datta, Shreya
    De, Abhishek
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2024, 90 (03): : 311 - 317
  • [14] Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment
    Shih, Pei-Yun
    Li, Chia-Jung
    Yong, Su-Boon
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 124
  • [15] Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors
    Nakashima, Chisa
    Yanagihara, Shigeto
    Otsuka, Atsushi
    ALLERGOLOGY INTERNATIONAL, 2022, 71 (01) : 40 - 46
  • [16] Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
    Nogueira, Miguel
    Torres, Tiago
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2021, 11 (04):
  • [17] Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
    Le, Michelle
    Berman-Rosa, Melissa
    Ghazawi, Feras M.
    Bourcier, Marc
    Fiorillo, Loretta
    Gooderham, Melinda
    Guenther, Lyn
    Hanna, Sameh
    Hong, H. Chih-Ho
    Landells, Ian
    Lansang, Perla
    Marcoux, Danielle
    Wiseman, Marni C.
    Yeung, Jensen
    Lynde, Charles
    Litvinov, Ivan V.
    FRONTIERS IN MEDICINE, 2021, 8
  • [18] Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis
    Wood, Hannah
    Chandler, Antoinette
    Nezamololama, Novin
    Papp, Kim
    Gooderham, Melinda J.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (06) : 746 - 754
  • [19] Treatment for atopic dermatitis with Janus kinase inhibitors: useful recommendations from expert opinions
    von Kobyletzki, Laura B.
    Svensson, Ake
    BRITISH JOURNAL OF DERMATOLOGY, 2024,
  • [20] Safety of Oral Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis
    Narla, Shanthi
    Silverberg, Jonathan I.
    DERMATITIS, 2023, : 366 - 386
12345